The biotech startup NanoZymeX has obtained CHF 150,000 from Venture Kick to advance a new platform for enzyme replacement therapy using lipid nanoparticles. The technology aims to improve treatment options for rare genetic conditions by increasing therapeutic activity in affected tissues.

生物技术初创公司NanoZymeX已从Venture Kick获得15万瑞士法郎，用于推进使用脂质纳米颗粒的酶替代疗法新平台。该技术旨在通过增加受影响组织中的治疗活性，改善罕见遗传病的治疗选择。

Enzyme replacement therapies are used to treat rare genetic disorders, but their effectiveness is often limited by poor delivery to the target tissue. In addition, immune responses to repeated treatments can limit long-term effectiveness.

酶替代疗法用于治疗罕见的遗传疾病，但其效果常常因难以送达目标组织而受到限制。此外，对重复治疗的免疫反应也可能限制其长期效果。

NanoZymeX

纳米酶X

is developing a lipid nanoparticle-based platform designed to transport therapeutic enzymes directly into target cells and lysosomes. By improving intracellular delivery and reducing immune reactions, the approach increases functional activity where it is most needed. Early preclinical studies show strong delivery efficiency and improved enzyme activity in relevant tissues.

正在开发一种基于脂质纳米颗粒的平台，旨在将治疗性酶直接运送到目标细胞和溶酶体中。通过改善细胞内递送并减少免疫反应，该方法在最需要的地方提高了功能性活性。早期的临床前研究表明，在相关组织中递送效率高且酶活性增强。

NanoZymeX’s technology targets lysosomal storage disorders, a group of rare diseases representing a multibillion-dollar therapeutic market, such as Pompe disease, an inherited lysosomal disorder..

NanoZymeX 的技术针对溶酶体贮积症，这是一组代表数十亿美元治疗市场的罕见疾病，例如庞贝病，一种遗传性溶酶体疾病。

The University of Basel spin-off is led by Boris Sevarika, Margarita C. Dinamarca, and Eva Hemmrich, who each bring complementary expertise in formulation development, neurobiology, and regulatory science.

巴塞尔大学的衍生公司由鲍里斯·塞瓦里卡、玛嘎丽塔·C·迪纳马尔卡和伊娃·海姆里希领导，他们在配方开发、神经生物学和监管科学领域各具互补的专业知识。

“The support from Venture Kick comes at a critical moment when scientific discoveries need to transition into real companies,” highlighted Boris Sevarika, co-founder of NanoZymeX. “This type of early funding provides the flexibility needed for company building, business development, and preparing the next stages of financing.

“Venture Kick的支持来得正是时候，科学发现需要转化为真正的公司，”NanoZymeX的联合创始人鲍里斯·塞瓦里卡强调说。“这种早期的资金提供了公司建设、业务发展以及准备下一阶段融资所需的灵活性。”

It fills a crucial gap between academic research and venture-backed biotech development.”.

它填补了学术研究和风险投资支持的生物技术开发之间的重要空白。

The Venture Kick philanthropic initiative provides seed funding to Swiss startups and offers a well-structured entrepreneurial path toward building a business. The CHF 150,000 from Venture Kick will help NanoZymeX further develop its lipid nanoparticle technology, conduct additional preclinical studies, and prepare scalable manufacturing.

Venture Kick慈善倡议为瑞士初创公司提供种子资金，并提供一条结构良好的创业路径以帮助建立企业。来自Venture Kick的15万瑞士法郎将帮助NanoZymeX进一步开发其脂质纳米粒子技术，进行更多的临床前研究，并准备可扩展的生产。

This will support future fundraising and the transition toward clinical trials..

这将支持未来的筹款活动，并向临床试验过渡。

(Press release/AJ)

（新闻稿/AJ）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送